Biohubx’s Post

What a privilege to bring together our International Precision Medicine & Diagnostics community in Basel this week to share ideas, new innovations, and best practices. The focus on patients and the goal of removing barriers within global healthcare systems to enable patient identification is both humbling and motivating. #bestteam #aiforhealthcare #digital #precisionmedicine #precisiondiagnostics #reimaginemedicine

Earlier this week, the RWD & RWE Club spoke with Brigham Hyde PhD, CEO at Atropos Health. We discussed closing the evidence gap in medicine with real world patient data. In addition, we chatted about the importance of democratizing access to data and how accelerating the generation of actionable evidence from a federated network of data will improve healthcare for everyone. You can now listen to the podcast recording of this conversation on the RWD & RWE Club website: https://lnkd.in/gbpGRjHY Brigham Hyde Matt Veatch Aaron Kamauu MD MS MPH #realworlddata #rwd #realworldevidence #rwe #datascience #clinicalresearch #drugdevelopment #healthcareanalytics #clinicaltrials #drugdevelopment #medicalinformatics #EHR #electronichealthrecords #EMR #electronicmedicalrecords #democratizingdata 

This should be interesting.

Please give us your thoughts about how to close the clinical practice gaps which keep patients from benefiting from Precision Medicine treatments.

Next week, our CEO, Dr. Will Briggs, and COO, Dr. Cat Kelly, will be attending the inaugural HLTH Europe event in Amsterdam. HLTH is known for its ability to bring together the health ecosystem, connecting leaders from around the world, including providers, payers, government, pharma, startups, and investors.   Will and Cat will be on the show floor, learning about the latest developments across healthcare, meeting potential partners, and providing insights into the latest innovations from Naitive. 💡 Why meet with us? 🤝 Get insights on how our technology could enhance clinical capabilities in the management of chronic diseases. 🤝 Learn about how opportunistic screening could redefine the care pathways for musculoskeletal health. Are you attending HLTH? Interested in how our approach could improve population health? Let's meet.   #HLTH #PopulationHealth #HealthcareInnovation

Listen to the podcast from the RWD & RWE Club featuring #AtroposHealth CEO and co-founder Dr. Brigham Hyde. Thanks to hosts Matt Veatch and Aaron Kamauu MD MS MPH for leading a lively discussion about closing the evidence gap in medicine to improve healthcare for everyone. Link to podcast below 👇 #realworlddata #rwd #realworldevidence #rwe #datascience #clinicalresearch #drugdevelopment #healthcareanalytics #clinicaltrials #drugdevelopment #medicalinformatics #EHR #electronichealthrecords #EMR #electronicmedicalrecords #democratizingdata 

Across the Kidneyverse — here's what caught my eye this week in headlines, media worth consuming, and our visual of the week. 𝐇𝐞𝐚𝐝𝐥𝐢𝐧𝐞𝐬: • Monogram Health signed a partnership w/ BCBS Arizona • Healthy.io celebrated its 1 MILLIONTH patient assessment • SeaStar Medical gets Canadian patent for its SCD tech • CMS announced record participation in ACO initiatives in 2024 • NKF Innovation Fund invests in ImmunoFree 𝐌𝐞𝐝𝐢𝐚 𝐰𝐨𝐫𝐭𝐡 𝐜𝐨𝐧𝐬𝐮𝐦𝐢𝐧𝐠: 1. How does home care adapt to a value-based care world? A McKnight's article takes a closer look at the growth of "at-risk" contracts and what it means for upfront payments for value-based entities in the the market. 2. Rock Health shared a post about a series of new virtual weight management launches fueled by digital health partnerships that's worth checking out. 3. Flare Capital's Michael A. Greeley writes an excellent blog. A post shared last week is about the state of healthtech in 2024 given a number of macro trends and how they've impacted investor sentiment and deal activity. 4. Acquired covers Novo Nordisk in their most recent episode. Add it to your queue for weekend listening. There are so many parallels and direct overlaps with the Kidneyverse, from its earliest days 100+ years ago to the current state of GLP-1s. Enjoy! *** Get more headlines, media, and my visual of the week in my next Across the Kidneyverse recap: 💫📡 https://lnkd.in/ea5s2kkt And if you like this new format, let me know! I want to keep things digestible, actionable, and interesting. What did I miss? Let us know what you're tracking this week... #healthtech #healthcare #innovation #valuebasedcare #digitalhealth -- Sources: [1] Monogram: https://lnkd.in/evVUHHgA [2] Healthy.io: https://lnkd.in/e8rTNU2p [3] McKnights: https://lnkd.in/e8sU7i5H [4] Rock Health: https://lnkd.in/eYa2AEYD [5] Greeley: https://lnkd.in/exaEBeYd [6] SeaStar: https://lnkd.in/eq6cw_vY [7] CMS: https://lnkd.in/eKpe2fn3 [8] NKF: https://lnkd.in/et49XXW9 [9] Acquired: https://lnkd.in/esnF_PBX

Join me tomorrow at the MassMedic MedTech Impact Symposium & Gala 2024 to explore the future of personalized healthcare. Our panel discussion on "Personalized Medicine: Expanding the Definition and Business Models". I will be joined by Arvind Ramadorai, Kevin P. Smith, Kimberly Gasuad, and Deepak Sahu as we pull apart the complexities and criticalities of getting this right. We'll dive deep into how personalized medicine is enabling patient care from various perspectives, discussing precision beyond diagnosis, adoption challenges, and innovative economic models to make personalized care a reality for all. #MassMedic #MedTechImpactSymposium #PersonalizedMedicine #HealthcareInnovation

Have you secured your spot? Get a better understanding of the Diaceutics Data Ecosystem and how you can use it to leverage your brand.

A couple of days on from Patients as Partners and what has really stuck with me are three key takeaways: The importance of measuring the impact of patient engagement, we have to prove this stuff works (there are still naysayers), if we are to truly implement long term change in the industry. Zack Pemberton-Whiteley spoke about this in the Impact measurement framework that Novartis have implemented. Bringing the patient in early on is critical, only then can we design studies that have meaningful patient led endpoints. Lea-Isabelle Proulx summarised this nicely, we have to be patient-centric not science-centric in how we design our protocols. We need to start treating designing the patient experience as a hard science, on a par with the molecule design. DE&I continues to be a hugely important topic, and one that should be at the forefront of every initiative. The panel led by Dr Heidi Green , discussing the 4 myths around DE&I was superb, and great to hear from Robina Weermeijer on what companies like Boehringer are doing here. Thanks to all the amazing speakers and patient advocates that made another great event. April Campbell (née. Veasey) Victoria Wright Sarah McKeown-Cannon #PatientEngagement #ClinicalTrials #PatientsEU2024